line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,-622966499.057326,AUROPHARMA.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.324698,AUROPHARMA.NS
Normalized EBITDA,2025-03-31 00:00:00,71729500000.0,AUROPHARMA.NS
Total Unusual Items,2025-03-31 00:00:00,-1918600000.0,AUROPHARMA.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,-1918600000.0,AUROPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,37895100000.0,AUROPHARMA.NS
Reconciled Depreciation,2025-03-31 00:00:00,16494200000.0,AUROPHARMA.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,130262400000.0,AUROPHARMA.NS
EBITDA,2025-03-31 00:00:00,69810900000.0,AUROPHARMA.NS
EBIT,2025-03-31 00:00:00,53316700000.0,AUROPHARMA.NS
Net Interest Income,2025-03-31 00:00:00,-4572400000.0,AUROPHARMA.NS
Interest Expense,2025-03-31 00:00:00,4572400000.0,AUROPHARMA.NS
Interest Income,2025-03-31 00:00:00,,AUROPHARMA.NS
Normalized Income,2025-03-31 00:00:00,39190733500.94267,AUROPHARMA.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,37895100000.0,AUROPHARMA.NS
Total Expenses,2025-03-31 00:00:00,264221100000.0,AUROPHARMA.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,AUROPHARMA.NS
Diluted Average Shares,2025-03-31 00:00:00,,AUROPHARMA.NS
Basic Average Shares,2025-03-31 00:00:00,,AUROPHARMA.NS
Diluted EPS,2025-03-31 00:00:00,,AUROPHARMA.NS
Basic EPS,2025-03-31 00:00:00,,AUROPHARMA.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,37895100000.0,AUROPHARMA.NS
Net Income Common Stockholders,2025-03-31 00:00:00,37895100000.0,AUROPHARMA.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,AUROPHARMA.NS
Net Income,2025-03-31 00:00:00,37895100000.0,AUROPHARMA.NS
Minority Interests,2025-03-31 00:00:00,23200000.0,AUROPHARMA.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,34835700000.0,AUROPHARMA.NS
Net Income Continuous Operations,2025-03-31 00:00:00,32917100000.0,AUROPHARMA.NS
Tax Provision,2025-03-31 00:00:00,15827200000.0,AUROPHARMA.NS
Pretax Income,2025-03-31 00:00:00,48744300000.0,AUROPHARMA.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,6218500000.0,AUROPHARMA.NS
Special Income Charges,2025-03-31 00:00:00,-1918600000.0,AUROPHARMA.NS
Other Special Charges,2025-03-31 00:00:00,1918600000.0,AUROPHARMA.NS
Write Off,2025-03-31 00:00:00,,AUROPHARMA.NS
Impairment Of Capital Assets,2025-03-31 00:00:00,,AUROPHARMA.NS
Restructuring And Mergern Acquisition,2025-03-31 00:00:00,,AUROPHARMA.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-4572400000.0,AUROPHARMA.NS
Total Other Finance Cost,2025-03-31 00:00:00,,AUROPHARMA.NS
Interest Expense Non Operating,2025-03-31 00:00:00,4572400000.0,AUROPHARMA.NS
Interest Income Non Operating,2025-03-31 00:00:00,,AUROPHARMA.NS
Operating Income,2025-03-31 00:00:00,49560200000.0,AUROPHARMA.NS
Operating Expense,2025-03-31 00:00:00,133958700000.0,AUROPHARMA.NS
Other Operating Expenses,2025-03-31 00:00:00,76164300000.0,AUROPHARMA.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,16494200000.0,AUROPHARMA.NS
Amortization,2025-03-31 00:00:00,,AUROPHARMA.NS
Depreciation Income Statement,2025-03-31 00:00:00,16494200000.0,AUROPHARMA.NS
Research And Development,2025-03-31 00:00:00,,AUROPHARMA.NS
Selling General And Administration,2025-03-31 00:00:00,,AUROPHARMA.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,AUROPHARMA.NS
General And Administrative Expense,2025-03-31 00:00:00,,AUROPHARMA.NS
Rent And Landing Fees,2025-03-31 00:00:00,,AUROPHARMA.NS
Gross Profit,2025-03-31 00:00:00,183518900000.0,AUROPHARMA.NS
Cost Of Revenue,2025-03-31 00:00:00,130262400000.0,AUROPHARMA.NS
Total Revenue,2025-03-31 00:00:00,313781300000.0,AUROPHARMA.NS
Operating Revenue,2025-03-31 00:00:00,313781300000.0,AUROPHARMA.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,AUROPHARMA.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.264886,AUROPHARMA.NS
Normalized EBITDA,2024-03-31 00:00:00,63832200000.0,AUROPHARMA.NS
Total Unusual Items,2024-03-31 00:00:00,0.0,AUROPHARMA.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,0.0,AUROPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,31729700000.0,AUROPHARMA.NS
Reconciled Depreciation,2024-03-31 00:00:00,15216600000.0,AUROPHARMA.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,126029000000.0,AUROPHARMA.NS
EBITDA,2024-03-31 00:00:00,63832200000.0,AUROPHARMA.NS
EBIT,2024-03-31 00:00:00,48615600000.0,AUROPHARMA.NS
Net Interest Income,2024-03-31 00:00:00,-2897100000.0,AUROPHARMA.NS
Interest Expense,2024-03-31 00:00:00,2897100000.0,AUROPHARMA.NS
Interest Income,2024-03-31 00:00:00,2857600000.0,AUROPHARMA.NS
Normalized Income,2024-03-31 00:00:00,31729700000.0,AUROPHARMA.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,31729700000.0,AUROPHARMA.NS
Total Expenses,2024-03-31 00:00:00,243831600000.0,AUROPHARMA.NS
Rent Expense Supplemental,2024-03-31 00:00:00,1204200000.0,AUROPHARMA.NS
Diluted Average Shares,2024-03-31 00:00:00,585851182.0,AUROPHARMA.NS
Basic Average Shares,2024-03-31 00:00:00,585851182.0,AUROPHARMA.NS
Diluted EPS,2024-03-31 00:00:00,54.16,AUROPHARMA.NS
Basic EPS,2024-03-31 00:00:00,54.16,AUROPHARMA.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,31729700000.0,AUROPHARMA.NS
Net Income Common Stockholders,2024-03-31 00:00:00,31729700000.0,AUROPHARMA.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,AUROPHARMA.NS
Net Income,2024-03-31 00:00:00,31729700000.0,AUROPHARMA.NS
Minority Interests,2024-03-31 00:00:00,40000000.0,AUROPHARMA.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,31689700000.0,AUROPHARMA.NS
Net Income Continuous Operations,2024-03-31 00:00:00,33608300000.0,AUROPHARMA.NS
Tax Provision,2024-03-31 00:00:00,12110200000.0,AUROPHARMA.NS
Pretax Income,2024-03-31 00:00:00,45718500000.0,AUROPHARMA.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,5186000000.0,AUROPHARMA.NS
Special Income Charges,2024-03-31 00:00:00,0.0,AUROPHARMA.NS
Other Special Charges,2024-03-31 00:00:00,-1540900000.0,AUROPHARMA.NS
Write Off,2024-03-31 00:00:00,2298100000.0,AUROPHARMA.NS
Impairment Of Capital Assets,2024-03-31 00:00:00,623700000.0,AUROPHARMA.NS
Restructuring And Mergern Acquisition,2024-03-31 00:00:00,986600000.0,AUROPHARMA.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-2897100000.0,AUROPHARMA.NS
Total Other Finance Cost,2024-03-31 00:00:00,216200000.0,AUROPHARMA.NS
Interest Expense Non Operating,2024-03-31 00:00:00,2897100000.0,AUROPHARMA.NS
Interest Income Non Operating,2024-03-31 00:00:00,2857600000.0,AUROPHARMA.NS
Operating Income,2024-03-31 00:00:00,43213400000.0,AUROPHARMA.NS
Operating Expense,2024-03-31 00:00:00,117802600000.0,AUROPHARMA.NS
Other Operating Expenses,2024-03-31 00:00:00,66330300000.0,AUROPHARMA.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,15216600000.0,AUROPHARMA.NS
Amortization,2024-03-31 00:00:00,5737700000.0,AUROPHARMA.NS
Depreciation Income Statement,2024-03-31 00:00:00,15216600000.0,AUROPHARMA.NS
Research And Development,2024-03-31 00:00:00,756300000.0,AUROPHARMA.NS
Selling General And Administration,2024-03-31 00:00:00,25024100000.0,AUROPHARMA.NS
Selling And Marketing Expense,2024-03-31 00:00:00,16847200000.0,AUROPHARMA.NS
General And Administrative Expense,2024-03-31 00:00:00,8176900000.0,AUROPHARMA.NS
Rent And Landing Fees,2024-03-31 00:00:00,1204200000.0,AUROPHARMA.NS
Gross Profit,2024-03-31 00:00:00,161016000000.0,AUROPHARMA.NS
Cost Of Revenue,2024-03-31 00:00:00,126029000000.0,AUROPHARMA.NS
Total Revenue,2024-03-31 00:00:00,287045000000.0,AUROPHARMA.NS
Operating Revenue,2024-03-31 00:00:00,287045000000.0,AUROPHARMA.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-28123330.0,AUROPHARMA.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.2621,AUROPHARMA.NS
Normalized EBITDA,2023-03-31 00:00:00,39967600000.0,AUROPHARMA.NS
Total Unusual Items,2023-03-31 00:00:00,-107300000.0,AUROPHARMA.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-107300000.0,AUROPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,19275000000.0,AUROPHARMA.NS
Reconciled Depreciation,2023-03-31 00:00:00,12445800000.0,AUROPHARMA.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,118997000000.0,AUROPHARMA.NS
EBITDA,2023-03-31 00:00:00,39860300000.0,AUROPHARMA.NS
EBIT,2023-03-31 00:00:00,27414500000.0,AUROPHARMA.NS
Net Interest Income,2023-03-31 00:00:00,54100000.0,AUROPHARMA.NS
Interest Expense,2023-03-31 00:00:00,1289500000.0,AUROPHARMA.NS
Interest Income,2023-03-31 00:00:00,1458900000.0,AUROPHARMA.NS
Normalized Income,2023-03-31 00:00:00,19354176670.0,AUROPHARMA.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,19275000000.0,AUROPHARMA.NS
Total Expenses,2023-03-31 00:00:00,220795300000.0,AUROPHARMA.NS
Rent Expense Supplemental,2023-03-31 00:00:00,1337600000.0,AUROPHARMA.NS
Diluted Average Shares,2023-03-31 00:00:00,585938609.0,AUROPHARMA.NS
Basic Average Shares,2023-03-31 00:00:00,585938609.0,AUROPHARMA.NS
Diluted EPS,2023-03-31 00:00:00,32.9,AUROPHARMA.NS
Basic EPS,2023-03-31 00:00:00,32.9,AUROPHARMA.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,19275000000.0,AUROPHARMA.NS
Net Income Common Stockholders,2023-03-31 00:00:00,19275000000.0,AUROPHARMA.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,AUROPHARMA.NS
Net Income,2023-03-31 00:00:00,19275000000.0,AUROPHARMA.NS
Minority Interests,2023-03-31 00:00:00,-1500000.0,AUROPHARMA.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,19276500000.0,AUROPHARMA.NS
Net Income Continuous Operations,2023-03-31 00:00:00,19276500000.0,AUROPHARMA.NS
Tax Provision,2023-03-31 00:00:00,6848500000.0,AUROPHARMA.NS
Pretax Income,2023-03-31 00:00:00,26125000000.0,AUROPHARMA.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,1288400000.0,AUROPHARMA.NS
Special Income Charges,2023-03-31 00:00:00,-107300000.0,AUROPHARMA.NS
Other Special Charges,2023-03-31 00:00:00,-132300000.0,AUROPHARMA.NS
Write Off,2023-03-31 00:00:00,0.0,AUROPHARMA.NS
Impairment Of Capital Assets,2023-03-31 00:00:00,239600000.0,AUROPHARMA.NS
Restructuring And Mergern Acquisition,2023-03-31 00:00:00,0.0,AUROPHARMA.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,54100000.0,AUROPHARMA.NS
Total Other Finance Cost,2023-03-31 00:00:00,115300000.0,AUROPHARMA.NS
Interest Expense Non Operating,2023-03-31 00:00:00,1289500000.0,AUROPHARMA.NS
Interest Income Non Operating,2023-03-31 00:00:00,1458900000.0,AUROPHARMA.NS
Operating Income,2023-03-31 00:00:00,25376000000.0,AUROPHARMA.NS
Operating Expense,2023-03-31 00:00:00,101798300000.0,AUROPHARMA.NS
Other Operating Expenses,2023-03-31 00:00:00,31288000000.0,AUROPHARMA.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,12445800000.0,AUROPHARMA.NS
Amortization,2023-03-31 00:00:00,4112900000.0,AUROPHARMA.NS
Depreciation Income Statement,2023-03-31 00:00:00,8332900000.0,AUROPHARMA.NS
Research And Development,2023-03-31 00:00:00,395100000.0,AUROPHARMA.NS
Selling General And Administration,2023-03-31 00:00:00,23481700000.0,AUROPHARMA.NS
Selling And Marketing Expense,2023-03-31 00:00:00,16857600000.0,AUROPHARMA.NS
General And Administrative Expense,2023-03-31 00:00:00,6624100000.0,AUROPHARMA.NS
Rent And Landing Fees,2023-03-31 00:00:00,1337600000.0,AUROPHARMA.NS
Gross Profit,2023-03-31 00:00:00,127174300000.0,AUROPHARMA.NS
Cost Of Revenue,2023-03-31 00:00:00,118997000000.0,AUROPHARMA.NS
Total Revenue,2023-03-31 00:00:00,246171300000.0,AUROPHARMA.NS
Operating Revenue,2023-03-31 00:00:00,246171300000.0,AUROPHARMA.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,-129690360.0,AUROPHARMA.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.1116,AUROPHARMA.NS
Normalized EBITDA,2022-03-31 00:00:00,46523100000.0,AUROPHARMA.NS
Total Unusual Items,2022-03-31 00:00:00,-1162100000.0,AUROPHARMA.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,-1162100000.0,AUROPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,26481500000.0,AUROPHARMA.NS
Reconciled Depreciation,2022-03-31 00:00:00,11265200000.0,AUROPHARMA.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,108151800000.0,AUROPHARMA.NS
EBITDA,2022-03-31 00:00:00,45361000000.0,AUROPHARMA.NS
EBIT,2022-03-31 00:00:00,34095800000.0,AUROPHARMA.NS
Net Interest Income,2022-03-31 00:00:00,-170400000.0,AUROPHARMA.NS
Interest Expense,2022-03-31 00:00:00,368400000.0,AUROPHARMA.NS
Interest Income,2022-03-31 00:00:00,316000000.0,AUROPHARMA.NS
Normalized Income,2022-03-31 00:00:00,27513909640.0,AUROPHARMA.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,26481500000.0,AUROPHARMA.NS
Total Expenses,2022-03-31 00:00:00,200662800000.0,AUROPHARMA.NS
Rent Expense Supplemental,2022-03-31 00:00:00,1241900000.0,AUROPHARMA.NS
Diluted Average Shares,2022-03-31 00:00:00,585938609.0,AUROPHARMA.NS
Basic Average Shares,2022-03-31 00:00:00,585938609.0,AUROPHARMA.NS
Diluted EPS,2022-03-31 00:00:00,45.19,AUROPHARMA.NS
Basic EPS,2022-03-31 00:00:00,45.19,AUROPHARMA.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,26481500000.0,AUROPHARMA.NS
Net Income Common Stockholders,2022-03-31 00:00:00,26481500000.0,AUROPHARMA.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,AUROPHARMA.NS
Net Income,2022-03-31 00:00:00,26481500000.0,AUROPHARMA.NS
Minority Interests,2022-03-31 00:00:00,10400000.0,AUROPHARMA.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,26471100000.0,AUROPHARMA.NS
Net Income Continuous Operations,2022-03-31 00:00:00,26471100000.0,AUROPHARMA.NS
Tax Provision,2022-03-31 00:00:00,7256300000.0,AUROPHARMA.NS
Pretax Income,2022-03-31 00:00:00,33727400000.0,AUROPHARMA.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,1345600000.0,AUROPHARMA.NS
Special Income Charges,2022-03-31 00:00:00,-1162100000.0,AUROPHARMA.NS
Other Special Charges,2022-03-31 00:00:00,-760100000.0,AUROPHARMA.NS
Write Off,2022-03-31 00:00:00,-22300000.0,AUROPHARMA.NS
Impairment Of Capital Assets,2022-03-31 00:00:00,1922200000.0,AUROPHARMA.NS
Restructuring And Mergern Acquisition,2022-03-31 00:00:00,,AUROPHARMA.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,-170400000.0,AUROPHARMA.NS
Total Other Finance Cost,2022-03-31 00:00:00,118000000.0,AUROPHARMA.NS
Interest Expense Non Operating,2022-03-31 00:00:00,368400000.0,AUROPHARMA.NS
Interest Income Non Operating,2022-03-31 00:00:00,316000000.0,AUROPHARMA.NS
Operating Income,2022-03-31 00:00:00,33002700000.0,AUROPHARMA.NS
Operating Expense,2022-03-31 00:00:00,92511000000.0,AUROPHARMA.NS
Other Operating Expenses,2022-03-31 00:00:00,23949700000.0,AUROPHARMA.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,11265200000.0,AUROPHARMA.NS
Amortization,2022-03-31 00:00:00,3286600000.0,AUROPHARMA.NS
Depreciation Income Statement,2022-03-31 00:00:00,7978600000.0,AUROPHARMA.NS
Research And Development,2022-03-31 00:00:00,652400000.0,AUROPHARMA.NS
Selling General And Administration,2022-03-31 00:00:00,21770200000.0,AUROPHARMA.NS
Selling And Marketing Expense,2022-03-31 00:00:00,14966700000.0,AUROPHARMA.NS
General And Administrative Expense,2022-03-31 00:00:00,6803500000.0,AUROPHARMA.NS
Rent And Landing Fees,2022-03-31 00:00:00,1241900000.0,AUROPHARMA.NS
Gross Profit,2022-03-31 00:00:00,125513700000.0,AUROPHARMA.NS
Cost Of Revenue,2022-03-31 00:00:00,108151800000.0,AUROPHARMA.NS
Total Revenue,2022-03-31 00:00:00,233665500000.0,AUROPHARMA.NS
Operating Revenue,2022-03-31 00:00:00,233665500000.0,AUROPHARMA.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,AUROPHARMA.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,AUROPHARMA.NS
Normalized EBITDA,2021-03-31 00:00:00,,AUROPHARMA.NS
Total Unusual Items,2021-03-31 00:00:00,,AUROPHARMA.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,,AUROPHARMA.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,AUROPHARMA.NS
Reconciled Depreciation,2021-03-31 00:00:00,,AUROPHARMA.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,AUROPHARMA.NS
EBITDA,2021-03-31 00:00:00,,AUROPHARMA.NS
EBIT,2021-03-31 00:00:00,,AUROPHARMA.NS
Net Interest Income,2021-03-31 00:00:00,,AUROPHARMA.NS
Interest Expense,2021-03-31 00:00:00,,AUROPHARMA.NS
Interest Income,2021-03-31 00:00:00,223700000.0,AUROPHARMA.NS
Normalized Income,2021-03-31 00:00:00,,AUROPHARMA.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,AUROPHARMA.NS
Total Expenses,2021-03-31 00:00:00,,AUROPHARMA.NS
Rent Expense Supplemental,2021-03-31 00:00:00,1225400000.0,AUROPHARMA.NS
Diluted Average Shares,2021-03-31 00:00:00,585938609.0,AUROPHARMA.NS
Basic Average Shares,2021-03-31 00:00:00,585938609.0,AUROPHARMA.NS
Diluted EPS,2021-03-31 00:00:00,91.05,AUROPHARMA.NS
Basic EPS,2021-03-31 00:00:00,91.05,AUROPHARMA.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,AUROPHARMA.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,AUROPHARMA.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,AUROPHARMA.NS
Net Income,2021-03-31 00:00:00,,AUROPHARMA.NS
Minority Interests,2021-03-31 00:00:00,,AUROPHARMA.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,AUROPHARMA.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,AUROPHARMA.NS
Tax Provision,2021-03-31 00:00:00,,AUROPHARMA.NS
Pretax Income,2021-03-31 00:00:00,,AUROPHARMA.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,AUROPHARMA.NS
Special Income Charges,2021-03-31 00:00:00,,AUROPHARMA.NS
Other Special Charges,2021-03-31 00:00:00,,AUROPHARMA.NS
Write Off,2021-03-31 00:00:00,281600000.0,AUROPHARMA.NS
Impairment Of Capital Assets,2021-03-31 00:00:00,0.0,AUROPHARMA.NS
Restructuring And Mergern Acquisition,2021-03-31 00:00:00,-1528500000.0,AUROPHARMA.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,AUROPHARMA.NS
Total Other Finance Cost,2021-03-31 00:00:00,149200000.0,AUROPHARMA.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,AUROPHARMA.NS
Interest Income Non Operating,2021-03-31 00:00:00,223700000.0,AUROPHARMA.NS
Operating Income,2021-03-31 00:00:00,,AUROPHARMA.NS
Operating Expense,2021-03-31 00:00:00,,AUROPHARMA.NS
Other Operating Expenses,2021-03-31 00:00:00,,AUROPHARMA.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,AUROPHARMA.NS
Amortization,2021-03-31 00:00:00,2537800000.0,AUROPHARMA.NS
Depreciation Income Statement,2021-03-31 00:00:00,,AUROPHARMA.NS
Research And Development,2021-03-31 00:00:00,688100000.0,AUROPHARMA.NS
Selling General And Administration,2021-03-31 00:00:00,24297200000.0,AUROPHARMA.NS
Selling And Marketing Expense,2021-03-31 00:00:00,15641700000.0,AUROPHARMA.NS
General And Administrative Expense,2021-03-31 00:00:00,8655500000.0,AUROPHARMA.NS
Rent And Landing Fees,2021-03-31 00:00:00,1225400000.0,AUROPHARMA.NS
Gross Profit,2021-03-31 00:00:00,,AUROPHARMA.NS
Cost Of Revenue,2021-03-31 00:00:00,,AUROPHARMA.NS
Total Revenue,2021-03-31 00:00:00,,AUROPHARMA.NS
Operating Revenue,2021-03-31 00:00:00,,AUROPHARMA.NS
